Literature DB >> 20953283

Translational benchmark risk analysis.

Walter W Piegorsch1.   

Abstract

Translational development - in the sense of translating a mature methodology from one area of application to another, evolving area - is discussed for the use of benchmark doses in quantitative risk assessment. Illustrations are presented with traditional applications of the benchmark paradigm in biology and toxicology, and also with risk endpoints that differ from traditional toxicological archetypes. It is seen that the benchmark approach can apply to a diverse spectrum of risk management settings. This suggests a promising future for this important risk-analytic tool. Extensions of the method to a wider variety of applications represent a significant opportunity for enhancing environmental, biomedical, industrial, and socio-economic risk assessments.

Entities:  

Year:  2010        PMID: 20953283      PMCID: PMC2954667          DOI: 10.1080/13669870903551662

Source DB:  PubMed          Journal:  J Risk Res        ISSN: 1366-9877


  39 in total

1.  Evaluation of the benchmark dose method for dichotomous data: model dependence and model selection.

Authors:  Salomon Sand; Agneta Falk Filipsson; Katarina Victorin
Journal:  Regul Toxicol Pharmacol       Date:  2002-10       Impact factor: 3.271

Review 2.  Critical issues in benchmark calculations from continuous data.

Authors:  Kenny Crump
Journal:  Crit Rev Toxicol       Date:  2002-05       Impact factor: 5.635

3.  A comparison of three methods for calculating confidence intervals for the benchmark dose.

Authors:  Mirjam Moerbeek; Aldert H Piersma; Wout Slob
Journal:  Risk Anal       Date:  2004-02       Impact factor: 4.000

4.  Model averaging using the Kullback information criterion in estimating effective doses for microbial infection and illness.

Authors:  Hojin Moon; Hyun-Joo Kim; James J Chen; Ralph L Kodell
Journal:  Risk Anal       Date:  2005-10       Impact factor: 4.000

5.  Estimating benchmark concentrations and other noncancer endpoints in epidemiology studies.

Authors:  A J Bailer; L T Stayner; R J Smith; E D Kuempel; M M Prince
Journal:  Risk Anal       Date:  1997-12       Impact factor: 4.000

6.  The use of benchmark dose methodology with acute inhalation lethality data.

Authors:  J R Fowles; G V Alexeeff; D Dodge
Journal:  Regul Toxicol Pharmacol       Date:  1999-06       Impact factor: 3.271

7.  Health assessment of phosgene: approaches for derivation of reference concentration.

Authors:  Jeffrey S Gift; Robert McGaughy; Dharm V Singh; Babasaheb Sonawane
Journal:  Regul Toxicol Pharmacol       Date:  2008-03-21       Impact factor: 3.271

8.  Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology.

Authors:  Myungsil Hwang; Eunkyung Yoon; Jayoung Kim; Dong Deuk Jang; Tae Moo Yoo
Journal:  Regul Toxicol Pharmacol       Date:  2008-12-25       Impact factor: 3.271

9.  A mechanism-based cancer risk assessment for 1,4-dichlorobenzene.

Authors:  Byron E Butterworth; Lesa L Aylward; Sean M Hays
Journal:  Regul Toxicol Pharmacol       Date:  2007-07-04       Impact factor: 3.271

Review 10.  Neurotoxicity modeling for risk assessment.

Authors:  R L Kodell; J J Chen; D W Gaylor
Journal:  Regul Toxicol Pharmacol       Date:  1995-08       Impact factor: 3.271

View more
  2 in total

1.  Exposure Enriched Case-Control (EECC) Design for the Assessment of Gene-Environment Interaction.

Authors:  Md Hamidul Huque; Raymond J Carroll; Nancy Diao; David C Christiani; Louise M Ryan
Journal:  Genet Epidemiol       Date:  2016-06-17       Impact factor: 2.135

2.  bmd: an R package for benchmark dose estimation.

Authors:  Signe M Jensen; Felix M Kluxen; Jens C Streibig; Nina Cedergreen; Christian Ritz
Journal:  PeerJ       Date:  2020-12-17       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.